CClinicalTrials.gg
CompletedNCT05499767HEPPIUpdated May 9, 2023

HEPPI: Efficacy of a Cognitive-Emotional Intervention for Homebound Older Adults

An interventional study of HEPPI in Mild Cognitive Impairment, Depressive Symptoms and Anxiety State, sponsored by University of Coimbra. Completed at 1 site in Portugal. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by University of Coimbra · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Sep 2021, registered Aug 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The main goal of this research is to assess the efficacy of a 10-week home-delivered cognitive-emotional intervention program for homebound older adults presenting Mild Cognitive Impairment (MCI) and depressive and/or anxiety symptoms. The Homebound Elderly People Psychotherapeutic Intervention (HEPPI) combines cognitive training, psychotherapeutic techniques, and compensatory strategy training, and was designed to optimize memory function and to reduce depressive or anxious symptomatology of these older adults.

A two-arm randomized controlled trial (RCT) is conducted to investigate the efficacy of the HEPPI among the homebound older population.

Read the detailed description

The present study aims to assess the efficacy of a cognitive-emotional intervention (the HEPPI program) for homebound older adults with MCI and depressive and/or anxious symptomatology.

The research design of the trial followed the methodological recommendations for conducting goropsychoterapy research. Moreover, a pilot RCT was conducted prior to the present RCT, in order to assess the feasibility, acceptability, and preliminary efficacy of the HEPPI. Appropriate adjustments to the HEPPI protocol were carried out considering the results.

The present study is a two-arm RCT comparing the intervention condition (HEPPI) to a treatment as usual (TAU) control group. The sample includes community-dwelling older adults who do not leave home more often than once a week. Homebound older adults are recruited from the community through contact with their health care networks. A minimum number of 79 participants per condition will be required (N=158). Accounting for an expected 20% attrition rate, an anticipated sample of 198 participants will be enrolled in the study. Participants who demonstrate interest in the study are informed of the goals and procedures of the research and asked to provide informed consent before eligibility assessment. Eligible participants are randomly assigned to the HEPPI or the TAU group.

Homebound older adults are asked to complete baseline, post-intervention, and 3-month follow-up assessments. Assessments include neuropsychological tests to assess cognition function, psychological health, subjective memory complaints, quality of life, functional status, perceived loneliness, and personality. The study procedures take place at the participants' homes.

02

Conditions studied

  • Mild Cognitive Impairment
  • Depressive Symptoms
  • Anxiety State

Keywords

  • Homebound Older Adults
  • Mild Cognitive Impairment
  • Depressive and Anxious Symptomatology
  • Cognitive-Emotional Intervention
  • Randomized Controlled Trial
03

In context

Cognitive Dysfunction

3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.

This study's enrollment of 199 is above the median of 65 across 2,808 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

University of Coimbra is the lead sponsor of 84 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Homebound older adults aged 65 years and older;
  • MoCA score 1 to 1.5 standard deviation below the mean for age- and education- adjusted norms;
  • FCSRT total immediate and delayed recall scores ≤ 35 and ≤ 12, respectively;
  • Presence of subjective memory complaints (SMCS score ≥ 3);
  • Presence of depressive symptomatology (GDS-30 score ≥ 11);
  • Presence of anxious symptomatology (GAI score ≥ 8);
  • No significant impact from cognitive impairment on daily functional capacity;
  • Residence in mainland Portugal;

Exclusion criteria

Exclusion Criteria:

  • Presence or history of significant neurological conditions;
  • Presence of severe psychiatric illnesses;
  • Presence of comorbid medical conditions associated with cognition decline;
  • Use of psychotropic medication for less than three months;
  • Presence of alcoholism or toxicomania;
  • Significant impairment of vision, hearing, communication, or manual dexterity.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    HEPPI

    The HEPPI group attends weekly 90-minute intervention sessions at the participants' homes.

    Behavioral: HEPPI

  • No intervention
    Treatment as Usual (TAU)

    The TAU group receives access to HEPPI at the end of the study.

Interventions

  • BehavioralHEPPI

    Homebound Elderly People Psychotherapeutic Intervention

06

What researchers measure

Primary outcomes

  1. Changes in Episodic Memory

    Logical Memory of the Wechsler Memory Scale-III (LM) \| Higher scores indicate a better outcome

    Time frame: Baseline, post-intervention, and 3-month follow-up

  2. Changes in Depressive Symptomatology

    Measured by Geriatric Depression Scale-30 (GDS-30) \| Lower scores indicate a better outcome

    Time frame: Baseline, post-intervention, and 3-month follow-up

  3. Changes in Anxious Symptomatology

    Measured by Geriatric Anxiety Inventory (GAI) \| Lower scores indicate a better outcome

    Time frame: Baseline, post-intervention, and 3-month follow-up

Secondary outcomes

  1. Changes in General Cognitive Function

    Measured by Addenbrooke's Cognitive Examination-Revised (ACE-R) \| Higher scores indicate a better outcome

    Time frame: Baseline, post-intervention, and 3-month follow-up

  2. Changes in Attentional Control

    Measured by Digit Symbol-Coding of the Wechsler Adult Intelligence Scale-III (DSC) \| Higher scores indicate a better outcome

    Time frame: Baseline, post-intervention, and 3-month follow-up

  3. Changes in Subjective Memory Complaints

    Measured by Subjective Memory Complaints Scale (SMCS) \| Lower scores indicate a better outcome

    Time frame: Baseline, post-intervention, and 3-month follow-up

  4. Changes in Perceived Quality of Life

    Measured by European Portuguese World Health Organization Quality of Life-Old Module (WHOQOL-OLD) \| Higher scores indicate a better outcome

    Time frame: Baseline, post-intervention, and 3-month follow-up

  5. Changes in Functional Status

    Measured by Adults and Older Adults Functional Assessment Inventory (IAFAI) \| Lower scores indicate a better outcome

    Time frame: Baseline, post-intervention, and 3-month follow-up

  6. Changes in Loneliness

    Measured by UCLA Loneliness Scale (UCLA) \| Lower scores indicate a better outcome

    Time frame: Baseline, post-intervention, and 3-month follow-up

Other outcomes

  1. Personality Traits

    Measured by NEO Five-Factor Inventory (NEO-FFI)

    Time frame: Baseline

07

Study locations

1 site
  • Center for Research in Neuropsychology and Cognitive Behavioral Intervention (CINEICC)
    Coimbra, Portugal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05499767
Lead sponsor
University of Coimbra
Collaborators
Foundation for Science and Technology, Portugal
Responsible party
Andreia Jesus (Principal Investigator, University of Coimbra) — Principal investigator
First posted
Aug 12, 2022
Start date
Sep 1, 2021
Primary completion
Mar 30, 2023
Completion
Mar 31, 2023
Last update
May 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion